Beijing Clinical Service Center Report issue

Academic/Hospital Phase 2

Organization Overview

First Clinical Trial
2011
NCT01391260
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Alternative names

Beijing Clinical Service Center

Active Ingredients

Drugs in Phase 2 Trials (3)

envafolimab (1 trial)

gefitinib (iressa) (1 trial)

sodium chloride (1 trial)

Drugs in Other Trials (1)

lactobacillus plantarum (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Hepatitis (Phase 2)

Hepatitis A (Phase 2)

Hepatitis B (Phase 2)

Hepatitis B, Chronic (Phase 2)

Hepatitis, Chronic (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 3
  • # of Trial APIs: 4